Quadrimune 10 mg, 15mg, 30mg, 40mg ORAL GRANULES
PDF Leaflet Revision Date: 09 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in children aged u2265 3 months and weighing u2265 3 to u2264 19.9 kg.
Dosage (summary)
Administered twice daily with food according to weight band.
Onset of Action / Duration
Onset: 6 weeks, Duration: variable.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to potential risks.
Key Drug Interactions
- Rifampicin
- St. John's Wort
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity to components
- Moderate to severe hepatic impairment
Common side effects
- Hypersensitivity reactions
- Nausea
- Vomiting
- Diarrhoea
- Fatigue
Counselling Points
- Screen for HLA-B*5701 allele
- Do not restart after hypersensitivity
- Monitor for symptoms of lactic acidosis
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Hypersensitivity reactions
Important Disclaimer
The Quadrimune 10 mg, 15mg, 30mg, 40mg ORAL GRANULES professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
